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Although little is known on the true prevalence of pancreatic cysts, physicians are currently more frequently confronted with
pancreatic cysts because of the increasing use of sophisticated cross-sectional abdominal imaging. Cystic lesions of the pancreas
comprise of a heterogeneous group of diagnostic entities, some of which are benign such as inﬂammatory pseudocysts or
serous cystadenomas and do not require resection when asymptomatic. Others like mucinous cysts or intraductal papillary
mucinous neoplasms (IPMN) have a malignant potential and in these cases surgical resection is often indicated. For this reason
an adequate distinction between the various cysts is crucial to optimize management strategy. Diﬀerent diagnostic methods that
could be of value in the diﬀerentiation include radiologic imaging techniques such as CT, MR, and endosonography. In addition,
ﬂuid aspiration for cytopathology, tumormarkers or molecular analysis is widely used. Diﬀerent guidelines are available but so
far no optimal diagnostic algorithm exists. We summarize the epidemiology, classiﬁcation, clinical presentation, diagnostics,
management, and future perspectives.
1.Introduction
As a result of the widespread use of cross-sectional imag-
ing, clinicians are confronted with pancreatic cysts with
increasing frequency [1]. The majority of these cysts are
asymptomatic, and the decision whether or not to operate is
not always straightforward. Although our knowledge of the
pathophysiology and pathobiology of pancreatic cysts is in-
creasing, relatively little is known about their natural history.
The apparent question is how to proceed after the
detection of an asymptomatic pancreatic cyst choosing one
ofthefollowingoptions:nofurtherinvestigations,additional
imaging ± ﬁne needle aspiration (FNA), surveillance, or sur-
gical/endoscopic treatment. Despite a spectacular improve-
mentindiagnosticmodalitiesinthepastdecades,diﬀerential
diagnosis and hence management of pancreatic cysts remain
controversial. Most centers have adopted a diﬀerential ap-
proach with follow up in case of absence of secondary
featuresofmalignancyandsurgicalresectionincaseofahigh
suspicion of malignancy. Multiple guidelines have appeared.
In this paper we will attempt to provide a comprehensive
overview of the epidemiology, diagnostic options, and man-
agement of pancreatic cysts.
2. Epidemiology
To date only a few studies have been performed investigating
the true prevalence of pancreatic cysts. We have recently
publishedastudyinwhich2803magneticresonanceimaging
(MRI)examinationswereretrospectivelyreviewedinagroup
of mostly asymptomatic patients who decided to undergo a
preventive screening abdominal MRI at their own initiative
and costs without referral of a physician. Prevalence was
2.4% and increased with age [1]. A study by Laﬀan et al.
reported a prevalence of 2.6% [2]. In retrospect, 2832 con-
secutive computed tomography (CT) scans were reviewed.
Patients with known pancreatic disease or symptoms related
to the pancreas were excluded. A prevalence of 13.5% was
found in another recent retrospective study in 616 patients2 Gastroenterology Research and Practice
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Figure 1: Prevalence of pancreatic cysts in relation to increasing
age.
using MRI [3]. Patients were excluded from this study if
they had a known or suspected history of pancreatic disease.
In all these studies increasing age correlated with a higher
prevalence of pancreatic cysts (Figure 1).
In an older Italian study reports of 24,039 MRI and
CT scans were retrospectively reviewed with a computerized
search. Pancreatic cysts were reported in 1.2% of which 58%
(0.7% of total study population) did not have a history of
pancreatitis [4]. The highest prevalence of pancreatic cysts
using a radiologic imaging techniquewasfound in astudy by
Zhang et al. [5]. Spin-echo MR images of 1444 patients were
reviewedforpancreaticcystsbytworadiologists,andpancre-
atic cysts were described in 19.6% of patients. Patients with
known history of pancreatic disease were not excluded from
this study.
In an autopsy study of 300 cases a stunning 24.3% were
found to have pancreatic cysts [6]. It is of note that this study
wasperformedinelderlypatients(morethan80%wereolder
than 65 years), and no information was provided of a possi-
ble history of pancreatic disease. The results of the described
studies are summarized in Table 1.T h eb r o a dr a n g eo f
prevalence values can be explained by the fact that studies
diﬀered in the selection of the study population, in-hospital
or out-patient based and whether patients with potential
pancreatic disease were excluded from analysis. Impor-
tantly, studies also diﬀered in which imaging modality was
employed with each technique having its distinct sensitivity
and speciﬁcity for detecting cysts.
3. Classiﬁcationof PancreaticCysticLesions
3.1. Nonneoplastic Pancreatic Cysts. The most common non-
neoplasticpancreaticcystsareserouscystadenomasandpan-
creatic pseudocysts, and these types are described in more
detail in this paper. Rare nonneoplastic pancreatic cysts in-
clude true cysts, retention cysts, and lymphoepithelial cysts.
3.1.1. Serous Cystadenoma. Patients with serous cystadeno-
mas(SCNs)arepredominantlyelderlywomenwithamedian
age of approximately 60 years, and the cysts can arise in any
region of the pancreas.
Classicalfeaturesofaserouscystadenomaincludemicro-
cystic morphology, a central area of calciﬁcation, and a
watery, nonviscous ﬂuid content. However a macrocystic
variant of serous cystadenomas exists and can easily be con-
fused with a pseudocyst or a mucinous cystadenoma [7–9].
Serous cystadenomas are lined by a glycogen-rich cuboidal
epithelium which can be shown with cytopathological anal-
ysis [10]. Although a small number of cases of malignant
serous cystadenocarcinomas have been described, it is gen-
erally believed that serous cystadenomas have virtually no
malignant potential [11]. Serous cystadenomas can be treat-
ed conservatively if the patient is asymptomatic. Surgery is
treatment of choice when a patient has symptoms or the
distinction between a serous cystadenoma and a mucinous
cystic neoplasm is not possible.
3.1.2. Pseudocysts. Pancreatic pseudocysts are ﬂuid collec-
tions arising from leakage of the pancreatic duct lacking an
epithelial lining. They usually occur following the course of
an acute pancreatitis, chronic pancreatitis or secondary to
an abdominal trauma [12]. The incidence of pseudocysts in
the phase of an acute pancreatitis is 5.1% to 16% [13–15]
whereas the incidence in chronic pancreatitis is higher with
percentages varying from 20% to 40% [16–18].
Radiologic imaging of pseudocysts frequently shows a
single cystic lesion, without septations or solid components.
Aspirated ﬂuid often has a low viscosity, high amylase, and
cytology which is consistent with an inﬂammatory origin.
The cysts are often ﬁlled with protease-free serous ﬂuid if
no connection to the pancreatic duct exists. Whereas size of
>6cm and duration of more than 6 weeks used to be main
indicators for intervention, currently symptomatology is the
main indicator for intervention.
3.2. Neoplastic Pancreatic Cysts. The majority of neoplas-
tic cysts are represented by mucinous cystic neoplasms
(MCNs) (10–49%) and intraductal papillary mucinous neo-
plasm (IPMN) (21–33%) [19, 20]. Solid pseudopapillary
neoplasms are less common. Other rare neoplastic cystic
lesions include cystic neuroendocrine tumors and acinar cell
cystadenocarcinomas but these will not be discussed in this
paper.
3.2.1. Mucinous Cystic Neoplasm. Patients with MCNs are
almost exclusively middle-aged women [21, 22], and most of
theMCNsappearinthebodyortailofthepancreasalthough
they occasionally may occur in the head. The average size
of the cysts is larger than 5cm at time of presentation [22–
24]. MCNs are generally macrocystic, thick-walled cysts that
typically lack communication with the ductal system [25,
26]. A microcystic MCN is rarely seen [27, 28]. They are
either unilocular or multilocular with a small number of
compartments [29]. Unique is the fact that MCNs contain a
mucinous, dense ovarian stroma surrounding the epithelial
cells, which is never seen in other cystic lesions. Therefore,
ovariantype stroma is considered a requisite to distinguish
MCNs from the other cystic neoplasms.
3.2.2. Intraductal Papillary Mucinous Neoplasms. IPMNs are
slightly more often seen in male patients and they are usuallyGastroenterology Research and Practice 3
Table 1: Characteristics of studies on pancreatic cyst prevalence.
Study Number of




de Jong et al. [1], 2010 2803 2.4 MRI Yes
Laﬀan et al. [2], 2008 2832 2.6 CT Yes
Lee et al. [3], 2010 616 13.5 MRI Yes
Spinelli et al. [4], 2004 24039 1.2 MRI and CT No
Zhang et al. [5], 2002 1444 19.6 MRI No
Kimura et al. [6], 1995 300 24.3 autopsy No
Table 2: Characteristics of diﬀerent pancreatic cysts.
MCN IPMN SPN SCN Pseudocyst
Sex distribution F > MM = FF > MF > MF = M
Age 40–60 60–70 20–30 60–70 All ages







Mixed solid and ﬂuid
with hemorrhage Microcystic Unilocular thick
wall
Fluid Viscous, clear Viscous, clear Thin, bloody Thin, clear Thin, dark
Malignant potential Yes Yes Yes No No
MCN: mucinous cystic neoplasm, IPMN: intraductal papillary mucinous neoplasm, SPN: solid pseudopapillary neoplasm, SCN: serous cystic neoplasm, PD:
pancreatic duct.
older at presentation than patients with MCNs or serous
cystadenomas. Most of the IPMNs arise in the head and
uncinate process of the pancreas, and they are typically
connected to the ductal system of the pancreas. IPMNs
comprise lesions of the main pancreatic duct, side branches
or a combination of these two. They have mixed features
of microcystic and macrocystic lesions, and the main pan-
creatic duct is often dilated. IPMNs contain mucinous ﬂuid
which is sometimes extruding from the ampulla of Vater.
An important diﬀerence in prevalence of malignancy exists
for main-duct and side-branch IPMNs. The prevalence of
malignancy for lesions of the main-duct IPMN is 57–92%
whereas it is 6–46% for lesions of side-branch IPMN [30].
3.2.3. Solid Pseudopapillary Neoplasms. Solid pseudopapil-
lary neoplasms (SPNs) are rare lesions which make up 1-2%
of all pancreatic cystic neoplasms [31, 32]. They are almost
exclusively found in young women with a median age of 30
years [33–35]. On the basis of the largest review [36], tumors
ranged in size from 0.5 to 34.5cm with a mean diameter of
6.08cm.
They are equally distributed throughout the pancreas
[36]. Solid pseudopapillary neoplasms often start as solid
tumors and undergo degeneration giving it a cystic appear-
ance on radiologic imaging [34]. On CT and MRI, the tumor
is often well circumscribed, encapsulated, and heteroge-
neous with hemorrhagic and cystic degeneration [32]. Solid
pseudopapillary neoplasms are tumors with relatively low
malignant potential, with a reported incidence of malignant
transformation of 15% [34]. Surgical resection of distant
metastases is justiﬁed due to the excellent long-term progno-
sis in the presence of metastatic disease [37]. Characteristics
of diﬀerent pancreatic cysts are summarized in Table 2.
4. ClinicalPresentation
Many patients with cystic lesions of the pancreas present
without abdominal complaints [38]. Lesions are often de-
tected when a radiologic examination is performed for an-
other reason or when an individual decides to undergo pre-
ventive screening investigations. When the pancreatic cyst is
symptomatic, patients may present with epigastric pain,
postprandial fullness, palpable mass, gastric outlet obstruc-
tion,nausea,vomiting,diarrhoea,steatorrhea,and/orweight
loss. Patients with IPMNs sometimes present with recurrent
episodes of pancreatitis. Side-branch IPMNs are more often
asymptomatic than main-duct IPMNs. MCNs and pseu-
dopapillaryneoplasmsarefrequentlylargeattimeofdiagno-
sis and symptoms are more common in these patients. When
an advanced cystic neoplasm exists, patients often present
with complaints similar to pancreatic adenocarcinoma such
as pain, weight loss, and jaundice [39].
5.Diagnostics
Diagnostic methods that can be valuable in the diﬀer-
entiation of pancreatic cysts include radiologic imaging
techniques such as abdominal ultrasound (US), computed
tomography (CT), and magnetic resonance imaging (MRI).
Endoscopic ultrasonography (EUS) and EUS-guided ﬁne4 Gastroenterology Research and Practice
Figure 2: Cystic lesion in the pancreatic head is punctured using a
linear array echo-endoscope.
needle aspiration (EUS-FNA) for cytopathologic examina-
tion, tumormarker determination, and molecular analysis
are also widely used (Figures 2, 3,a n d4).
Transabdominal ultrasonography is a safe imaging tech-
nique without radiation exposure which is helpful in the dif-
ferentiation of solid and cystic lesions. It is currently widely
used in the evaluation of abdominal complaints. As a result,
cystic lesions are often initially detected with this modality. It
is however not the imaging of ﬁrst choice since it is diﬃcult
to visualize the complete pancreas due to overlying bowel or
fat, and it is rather operator dependent. CT is often used in
the diagnostic workup. It is a widely used imaging technique
to visualize and diﬀerentiate pancreatic cysts based on
morphologicfeaturesassize,microcystic/macrocysticaspect,
presence of septations, nodules, and calciﬁcations [40, 41].
MRI has the additional advantage to show a possible connec-
tion with the pancreatic duct which on T2-weighted image
sequences is better visualized than with CT [42]. Another
advantage of MRI, especially for follow up of the cysts, is the
lack of radiation exposure.
EUS has emerged as a useful diagnostic technique in
the evaluation of pancreatic cystic lesions, providing ﬁne
detail on the characteristics of the cyst because of the very
high spatial resolution. It has therefore been suggested as
an ideal imaging technique for pancreatic cysts [27, 43–
45]. EUS can image characteristics of the cysts as well as
the parenchymal changes and has a role in determining
the resectability if malignancy is present [46]. Despite the
fact that EUS is presently widely used for the diﬀerential
diagnosis, a number of points of discussion still exist. Since
EUS is invasive, technically diﬃcult, and expensive, it is not
available in all hospitals. Furthermore there is a substantial
interobserver agreement between endosonographers. In a
multicenter study 8 experienced endosonographers reviewed
videotapes of 31EUS procedures of pancreatic cysts. In this
study there was only poor to moderate agreement for the





Figure 3: (a) EUS image of a malignant IPMN in the head of the
pancreas. (b) MRI image of a malignant IPMN in the head of the
pancreas.
and EUS features [47]. An advantage of EUS is the possibility
to perform FNA for analysis of the cyst ﬂuid. EUS-FNA is
considered a safe technique to obtain pancreatic cyst ﬂuid
with rare, mostly mild complications, but infection, pan-
creatitis, and intracystic haemorrhage have been reported




of punctures to a minimum and attempt to aspirate all ﬂuid
from the cyst whenever possible. Intracystic hemorrhage is
a complication that occurred in 6% of all cases reported by
Varadarajulu et al. but most of the complications were mild
and did not need further medical intervention [50].
Cytological evaluation of pancreatic cyst ﬂuid is widely
used,andseveralstudiesreportasensitivityofapproximately
50% for the diﬀerentiation of mucinous and nonmucinous
pancreatic neoplasms [51–53]. However, other studies show
less positive results since cytopathology is often nondi-





Figure 4: (a) EUS image of a serous cystadenoma in the head of the
pancreas. (b) MRI image of a serous cystadenoma in the head of the
pancreas.
ﬂuid [54, 55]. Biochemical analysis of cyst ﬂuid and tumor
markers have been evaluated for several years with the
underlying thought that markers secreted into the cyst ﬂuid
identify the epithelial lining. Amylase is usually elevated
in pseudocysts and IPMNs and low in MCNs and serous
cystadenomas. Of the tumor markers, CEA is considered
the best discriminant marker to diﬀerentiate between a
mucinous and a nonmucinous cyst [54, 56]. A low CEA level
(<5ng/mL) has been shown to have a sensitivity between
50% and 100% and a speciﬁcity of 77–95% to diﬀerentiate
betweenmucinousandnonmucinouscysts[51].Pseudocysts
and serous cystadenomas generally have a low CEA value.
Currently, the most widely used cutoﬀ for an elevated CEA
is 192ng/mL, which was established in a study by Brugge
et al. as diagnostically sensitive in 75% and speciﬁc in 84%
to discriminate between mucinous and nonmucinous cysts
[54]. Altogether, the current yield of FNA is small, which
can be caused by the microcystic aspect of a cyst, the high
viscosity of the ﬂuid or the minimum amount of ﬂuid that
is needed for certain examinations of the ﬂuid. The standard
use of a 19 G needle could be helpful to aspirate both larger
cysts and cysts which contain ﬂuid with a high viscosity.
6. Management (Guidelines)
The most recent guideline for the management of pancreatic
cyst was published in 2007 by Khalid and Brugge [57]. In
this guideline the authors advice to thoroughly evaluate each
incidental pancreatic cyst since many cysts are premalignant
(MCN and IPMN). The initial imaging test proposed is a
contrast-enhanced triphasic multidetector CT scan, which
may be followed by EUS-FNA in particular cases when FNA
is needed for CEA level or to puncture a solid component.
Resection is recommended in all MCNs and main-duct
IPMNs. Firm recommendations for the management of
branch-duct IPMNs are not provided. Serous cystadenomas
should only be resected if symptomatic or if the diagnosis
remains in doubt. All pseudopapillary neoplasms should be
considered for resection. No general guidelines are provided
for the interval of follow up when surgery is not undertaken.
The authors state that this decision depends on the kind of
lesion and the reason why surgery was not performed.
The American Society for Gastrointestinal Endoscopy
issued a guideline on the use of EUS in the management of
pancreatic cysts [58]. Cystic lesions of the pancreas require
diagnostic evaluation regardless of size, and EUS alone is
considered not accurate enough to deﬁnitively diagnose the
type of cystic lesion or to determine its malignant potential.
Furthermore, FNA is advised with a low sensitivity of
cytologic analysis but a high speciﬁcity for MCN and malig-
nancies. Biochemical analysis may provide clinically useful
information but cannot provide a deﬁnitive diagnosis or
determine whether the lesion is malignant. In this guideline
it is stated that there are currently no accepted endoscopic
therapies for cystic neoplasms of the pancreas, and there is
a role for endoscopic drainage of inﬂammatory pancreatic
ﬂuid collections.
In 2005 international consensus guidelines for the man-
agement of IPMNs and MCNs were published in which a
list of clinically relevant questions and answers is provided
[30]. The recommendation is to resect all main-duct and
mixed variant IPMNs regardless of size as long as the patient
is a good surgical candidate. Asymptomatic side-branch
IPMNs can be followed with CT or MRI as long as there
are no mural nodes, dilatation of the main duct or growth
in size. The authors do not explicitly state that all branch-
duct IPMNs >3cm should be resected. More data based on
branch-duct IPMNs >3cm without main-duct dilatation or
mural nodules are needed to determine if all branch-duct
IPMNs >3cm should be resected immediately. The authors
state that MCNs should always be resected unless there are
contraindications for surgery.
7.FutureDevelopments
New methods to improve the yield of FNA are urgently
required. Existing tumor markers have only limited value,
and more sensitive biomarkers need to be identiﬁed. New
techniquesincluding proteomics and molecularanalysismay
be helpful for the diﬀerential diagnosis of pancreatic cysts
[59].
Also the development of new techniques to minimize the
ﬂuid needed for examinations may well be useful. Further-
more, the development of new techniques to increase the cel-
lularity of the obtained ﬂuid could be helpful. Three reports
have been recently published, studying a new type of brush6 Gastroenterology Research and Practice
(EchoBrush, Cook Medical) to improve the yield of cyto-
logic examination [60–62]. These studies suggest that this
relatively new technique improves the yield, but larger
randomized trials are necessary to conﬁrm these results and
to deﬁne the safety proﬁle of this more aggressive approach.
Currently, no accepted endoscopic treatment option for
neoplastic cystic lesions is available but a few experimental
studies have been performed to determine the safety and
eﬀectiveness of EUS-guided ethanol lavage with paclitaxel to
treat pancreatic cysts [63–65] .T h eﬁ r s ts t u d i e sr e p o r tt h a t
this technique is a safe and feasible but larger studies with
longer follow up are necessary.
8. Conclusion
Patients presenting with pancreatic cysts have to be thor-
oughly evaluated. Cross-sectional imaging should be used
for the morphological characterization, and EUS-FNA for
ﬂuid and tissue sampling could be used in particular cases
to discriminate between mucinous and nonmucinous cysts.
Management should be based upon on carefully weighting
the malignant potential of a pancreatic cystic lesions and
t h er i s ko fs u r g e r y .L a r g e rp r o s p e c t i v es t u d i e sw i t hl o n g e r
followupareneededtoincreasetheknowledgeofthenatural
history of pancreatic cysts.
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